Tag: Absorb
TCT 2017: Advances in device technology needed to improve outcomes with Absorb
Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular sc...
“Low commercial sales” prompt Abbott to pull the plug on selling Absorb
Abbott has announced that it is to stop selling its first-generation bioresorbable vascular scaf...
EuroPCR 2017: Study finds no association between implantation technique and risk of scaffold thrombosis
A study—AIDA (Amsterdam investigator-initiated Absorb strategy all-comers trial)—presented at Eu...
EuroPCR 2017: ABSORB China and ABSORB show both comparable safety and efficacy to Xience at three years.
Data presented from ABSORB China and ABSORB Japan at EuroPCR (16–19 May, Paris, France) show the...
Absorb GTS to be restricted to registry use only in Europe
Abbott Vascular has written a letter to European physicians to say that from 31 May, its bioreso...
The use of bioresorbable scaffold in clinical practice
At JIM 2017 (9-11 February, Milan, Italy), we spoke to Bernardo Cortese (Interventional Cardiology, ...
ACC 2017: Two-year rate of target lesion failure significantly higher with Absorb
Two-year data from the ABSORB III study indicate that a bioresorbable vascular scaffold (Absorb,...
The implications of ABSORB II three-year results for the future of bioresorbable scaffolds
The idea of a fully bioresorbable scaffold is attractive as the need for mechanical support for ...
TCT 2016: Three-year data fail to show Absorb to be superior or even non-inferior to Xience
According to the three-year results of the ABSORB II trial, a bioresorbable vascular scaffold (A...
TCT 2016: Late-breakers and first report investigations announced
The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi...
Absorb now available in the USA following FDA approval
Five years after receiving the CE mark, Abbott Vascular’s bioresorbable vascular scaffold (A...
Risk of device thrombosis may be significantly higher with Absorb than with Xience, Promus or Orsiro
A network meta-analysis, published in JACC: Cardiovascular Interventions, indicates that three c...
